Flash Therapeutics
Boston
About Flash Therapeutics
Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $5.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2016)
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/flash-therapeutics-179506 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.